Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 9/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | PROKR1 | Q8TCW9 | 2/20 | 0.37 |
| ▸ | RORC | P51449 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL641109 | 0.94 | F2R (0.49) | F2RNOTUMDPP4MEN1HPGD | |
| SCHEMBL1057305 | 0.91 | F2R (0.43) | F2RTACR1RORC | |
| SCHEMBL1052100 | 0.88 | F2R (0.52) | F2RLIPEPROKR1 | |
| SCHEMBL641596 | 0.86 | F2R (0.68) | F2RNOTUMMEN1HPGDTSHR | |
| SCHEMBL485914 | 0.86 | F2R (0.67) | F2RNOTUMKMT2ATACR1AKR1C3 | |
| SCHEMBL640805 | 0.86 | F2R (0.55) | F2RNOTUMMEN1HPGDTSHR | |
| SCHEMBL1056589 | 0.86 | F2R (0.41) | F2RTACR1RORC | |
| SCHEMBL1052035 | 0.86 | F2R (0.50) | F2RNOTUMDPP4MEN1KMT2A | |
| SCHEMBL3800390 | 0.85 | F2R (0.67) | F2RNOTUMMEN1HPGDTSHR | |
| SCHEMBL9894509 | 0.85 | F2R (0.56) | F2RNOTUMMEN1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252948-A1 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| US-20130252948-A1 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| US-8440657-B2 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-14 | — | — | US | disclosed |
| US-8440657-B2 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-14 | — | — | US | disclosed |
| US-8440657-B2 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-14 | — | — | US | disclosed |
| US-20120220563-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-30 | — | — | US | disclosed |
| US-20120220563-A1 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-08-30 | — | — | US | disclosed |
| US-8202862-B2 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8202862-B2 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8202862-B2 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2012-06-19 | — | — | US | disclosed |
| US-8084469-B2 | Substituted piperidines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-27 | — | — | US | disclosed |
| US-20110021489-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| US-20110021489-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
| WO-2010136138-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136138-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136144-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136144-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305111-A1 | SUBSTITUTED PIPERIDINES | Bayer Schering Pharma (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305111-A1 | SUBSTITUTED PIPERIDINES | Bayer Schering Pharma (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305111-A1 | SUBSTITUTED PIPERIDINES | Bayer Schering Pharma (DE) | 2010-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021489-A1 | SUBSTITUTED PIPERIDINES | VHL, PIR, PIGO | F2R 1339/4885NOTUM 876/4885DPP4 141/4885 |
| US-20100305111-A1 | SUBSTITUTED PIPERIDINES | VHL, PIR, PTGIS | F2R 1245/4885NOTUM 878/4885DPP4 102/4885 |
| US-20120220563-A1 | Substituted piperidines | VHL, PIR, PIGO | F2R 1339/4885NOTUM 876/4885DPP4 141/4885 |
| US-20130252948-A1 | Substituted piperidines | VHL, PIR, PTGIS | F2R 1245/4885NOTUM 878/4885DPP4 102/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.